Drug Trial Radar · NCT06908577
An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
254
Actual
Start
Apr 7, 2025
Primary completion
Nov 25, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants.
Conditions
- Healthy Participants
Interventions
TozorakimabDrug
Tozorakimab will be administered as a single SC dose using an AI or APFS device on Day 1.
Autoinjector (AI) DeviceDevice
AI device will be used to administer single SC dose of tozorakimab on Day 1.
Accessorised Prefilled Syringe (APFS) DeviceDevice
APFS device will be used to administer single SC dose of tozorakimab on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under concentration-time curve from time 0 to infinity (AUCinf) of tozorakimabTime frame: From Day 1 to Day 113
- Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of tozorakimabTime frame: From Day 1 to Day 113
- Maximum observed drug concentration (Cmax) of tozorakimabTime frame: From Day 1 to Day 113
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Glendale, California
Research Site
Baltimore, Maryland
Research Site
Berlin, Germany
Research Site
Harrow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.